EP2772261B1 - Orally administered adsorbent containing activated carbon fiber - Google Patents

Orally administered adsorbent containing activated carbon fiber Download PDF

Info

Publication number
EP2772261B1
EP2772261B1 EP12838141.5A EP12838141A EP2772261B1 EP 2772261 B1 EP2772261 B1 EP 2772261B1 EP 12838141 A EP12838141 A EP 12838141A EP 2772261 B1 EP2772261 B1 EP 2772261B1
Authority
EP
European Patent Office
Prior art keywords
activated carbon
acfs
carbon fiber
fiber
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12838141.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2772261A4 (en
EP2772261A1 (en
Inventor
Yasumi Nishiwaki
Takashi Murakami
Nobuaki Eto
Keiichiro Imaizumi
Akihito OHTAKI
Kenji Shimazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Priority to SI201231142T priority Critical patent/SI2772261T1/en
Priority to PL12838141T priority patent/PL2772261T3/pl
Priority to RS20180154A priority patent/RS56902B1/sr
Priority to MEP-2018-38A priority patent/ME02959B/me
Publication of EP2772261A1 publication Critical patent/EP2772261A1/en
Publication of EP2772261A4 publication Critical patent/EP2772261A4/en
Application granted granted Critical
Publication of EP2772261B1 publication Critical patent/EP2772261B1/en
Priority to HRP20171970TT priority patent/HRP20171970T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/20—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbon; comprising carbon obtained by carbonising processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004—Sorbent size or size distribution, e.g. particle size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28023—Fibres or filaments
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28057—Surface area, e.g. B.E.T specific surface area
    • B01J20/28066—Surface area, e.g. B.E.T specific surface area being more than 1000 m2/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28078—Pore diameter
    • B01J20/2808—Pore diameter being less than 2 nm, i.e. micropores or nanopores
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/30—Active carbon
    • C01B32/312—Preparation
    • C01B32/336—Preparation characterised by gaseous activating agents
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • D01F9/08—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
    • D01F9/12—Carbon filaments; Apparatus specially adapted for the manufacture thereof
    • D01F9/14—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments

Definitions

  • This invention relates to adsorbents for oral administration and, in particular, to a uremic toxin adsorbent for oral administration comprising activated carbon fibers (sometimes referred to hereinafter as "ACFs") as an active component for use in treating or preventing kidney diseases or dialysis complications.
  • ACFs activated carbon fibers
  • Kidney diseases generally include pathological conditions in the acute and chronic phases, and particularly chronic kidney disease affects about 11% of adults in Japan, the number of which is increasing year by year (Non-patent Literature 1). With decrease in kidney function, chronic kidney disease worsens into uremia due to accumulation in the body such as blood of a harmful toxic substance (a uremic toxin) which is in principle to be excreted from the body. It is thought that uremia itself induces further kidney dysfunction and also does promote progression of chronic kidney disease, although uremia may cause muscle weakness, abnormal sensation, and even hypertension, anemia and cardiac hypertrophy in addition to sleeplessness, headache, bad breath, and appetite reduction (Non-patent Literature 2).
  • a harmful toxic substance a uremic toxin
  • an adsorbent as disclosed in Patent Literature 1 comprises a porous spherical carbonaceous substance having specific functional groups (hereinafter sometimes referred to as "spherical activated carbon") and can achieve intestinal adsorption and excretion in feces of uremic toxins and precursors thereof (for example, indoleacetic acid) accumulated in vivo, resulting in a reduction in the uremic toxins (for example, indoxylsulfuric acid) in the blood.
  • spherical activated carbon a porous spherical carbonaceous substance having specific functional groups
  • Patent Literature 2 Patent Literature 3, Non-patent Literature 3, Non-patent Literature 4, Non-patent Literature 5, Non-patent Literature 6 and Non-patent Literature 7
  • JP-A-2006 008 602 discloses the use of carbon nanotubes as oral uremic toxin adsorption agent for ameliorating/treating uremia, chronic renal failure and renal insufficiency.
  • Adsorbents for oral administration comprising spherical activated carbon, however, have some disadvantages; these adsorbents have insufficient adsorption performance and are to be administered at high daily doses accordingly, which causes gastrointestinal symptoms, such as constipation and anorexia.
  • patients with chronic kidney disease who must control water intake, have to swallow a high dose of 6 g per day of adsorbents for oral administration comprising spherical activated carbon with a small amount of water, which imposes a great strain on the patients.
  • Non-patent Literature 8 Non-patent Literature 8
  • adsorbents include medicinal carbon (sometimes referred to hereinafter as "powdered activated carbon").
  • Orally administered medicinal carbon can be used as one of therapeutic approaches to acute drug intoxication that occurs when agrichemicals such as insecticides and herbicides, analgesics and hypnotics are intentionally or accidentally administered in high doses for a short time, which is a pathological condition causing consciousness disorder, respiratory and/or circulatory disorders, or disorders of organs such as kidney and liver.
  • the medicinal carbon can adsorb or precipitate a poison present in the digestive tract to suppress absorption of the poison into the body.
  • the medicinal carbon is required to be administered in an amount of 40 to 60 g per kg of body weight for adults and of 1 g even for children (Non-patent Literature 9), which indicates that adsorption performance of the medicinal carbon as a uremic toxin adsorbent is unclear.
  • An object of the present invention is to provide an adsorbent for oral administration comprising ACFs that have a high adsorption or removal performance by adsorbing or removing toxic substances in vivo greatly and rapidly.
  • Another object of the present invention is to provide an ACF-containing therapeutic or prophylactic drug for kidney diseases or dialysis complications.
  • the present inventors have diligently researched to seek an adsorbent for oral administration having an adsorption performance far superior to those of adsorbents for oral administration comprising conventional spherical activated carbon, and as a result, have found that an adsorbent for oral administration having an excellent adsorption performance and/or initial rate of absorption can be obtained by using ACFs as an active component.
  • the present invention is as follows:
  • the adsorbent for oral administration according to the present invention has a higher adsorption performance or a superior initial rate of absorption, and can adsorb harmful toxic substances in vivo rapidly in the intestinal tract and consequently lower the dose.
  • the adsorbent for oral administration according to the present invention has a low adsorptivity toward high molecular weight compounds such as enzymes that are essential to living organism, and therefore, a sufficient selective adsorptivity.
  • the inventive adsorbent becomes easy to swallow because it is significantly small in size compared to conventional adsorbents for oral administration.
  • the adsorbent for oral administration according to the present invention becomes a superior therapeutic or prophylactic drug for kidney diseases and dialysis complications compared to conventional adsorbents for oral administration.
  • the ACFs in the present invention are prepared by curing acrylonitrile-based fibers, phenolic fibers, and fiberized pitch (byproducts from petroleum, coal, coal-tar and the like) by oxidation treatment, followed by activation.
  • the ACFs have the following properties:
  • the ACFs in the present invention have a cross-sectional diameter of the fiber (average diameter) of 5 to 50 ⁇ m preferably, and more preferably 5 to 30 ⁇ m.
  • the ACFs having a diameter of less than 5 ⁇ m are not preferred due to concerns about residual ACFs in vivo and cellular uptake although the amount and rate of adsorption increases.
  • the ACFs having a diameter of more than 50 ⁇ m are not preferred since the rate of adsorption slows and the effect as an adsorbent for oral administration diminishes.
  • the term "average diameter" as used in the present invention refers to a Dv50 value in the cross-sectional diameter of the fiber as described below.
  • the diameter can be varied depending on the fineness of the raw material fiber used and the degree of drawing and/or shrinking in intermediate treatment processes such as flame-proofing, and the degree of activation.
  • the ACFs of the present invention may be of any cross-sectional shape such as round, oval, chrysanthemum-shaped, and polygonal, depending on the cross-sectional shape of the raw material fiber used.
  • the ACFs in the present invention may have any fiber length.
  • the fiber length is 10 to 5000 ⁇ m and more preferably 15 to 3000 ⁇ m.
  • the fiber length is still more preferably 20 to 3000 ⁇ m, and further preferably 90 to 3000 ⁇ m.
  • the ACFs having a length of more than 5000 ⁇ m are not preferred since such ACFs gather together in bundles, and pill easily. For improving this problem, it is effective to shorten the fiber length.
  • common grinders may be used. For example, a ball mill, a jet mill, or a mechanical rotary grinder can grind the fiber.
  • the particulate formed by destruction of the fiber may be removed through sieving or with a classifier.
  • the adjustment of the fiber length is accomplished by shredding long fibers or subjecting long fiber, felt, or textile ACFs to grinding (milling). Certain treatments such as sieving can be carried out for equalizing the fiber length.
  • the ACFs in the present invention preferably have a specific surface area of 250 to 4000 m 2 /g, more preferably 800 to 4000 m 2 /g, and still more preferably 600 to 3500 m 2 /g.
  • the ACFs having a specific surface area of less than 250 m 2 /g are not preferred since the adsorbed amount of uremic toxins decreases.
  • the ACFs having a specific surface area of more than 4000 m 2 /g are not preferred since they have enlarged pores, thereby decreasing the adsorbed amount of low-molecular-weight substances such as uremic toxins, while increasing the adsorbed amount of beneficial high-molecular-weight substances,such as enzymes, resulting in a decrease in the selective adsorptivity toward uremic toxins.
  • the specific surface area is preferably 900 to 3000 m 2 /g, still more preferably 1000 to 3000 m 2 /g, further preferably 1400 to 2700 m 2 /g, still more preferably 1400 to 2500 m 2 /g, and further preferably 1400 to 2200 m 2 /g.
  • the ACFs in the present invention preferably have a total pore volume of 0.2 to 3.0 mL/g and more preferably 0.4 to 2.0 mL/g.
  • the ACFs having a total pore volume of less than 0.2 mL/g are not preferred since the amount of uremic toxins adsorbed decreases.
  • the ACFs having a total pore volume of more than 3.0 mL/g are not preferred since they have enlarged pores, thereby decreasing the adsorbed amount of low-molecular-weight substances such as uremic toxins, while increasing the adsorbed amount of beneficial high-molecular-weight substances such as enzymes, resulting in a decrease in the selective adsorptivity toward uremic toxins.
  • the total pore volume is more preferably 0.5 to 1.8 mL/g, still more preferably 0.8 to 1.8 mL/g, and further preferably 1.0 to 1.7 mL/g.
  • the ACFs in the present invention preferably has a micropore volume of 0.1 to 2.0 mL/g and more preferably 0.3 to 1.5 mL/g.
  • the ACFs having a micropore volume of less than 0.1 mL/g are not preferred since the adsorbed amount of small molecules such as uremic toxins decreases.
  • the micropore volume is still more preferably 0.5 to 1.0 mL/g, and further preferably 0.6 to 0.8 mL/g.
  • the ACFs in the present invention preferably have a mesopore volume of 0.8 mL/g or less, more preferably 0.7 mL/g or less, and still more preferably 0.5 mL/g or less.
  • the ACFs having a mesopore volume of more than 0.8 mL/g are not preferred since the adsorbed amount of beneficial high-molecular-weight compounds such as enzymes increases.
  • the ACFs in the present invention preferably have a macropore volume of 0.3 mL/g or less, and more preferably 0.2 mL/g or less.
  • Any fiber that is commonly used as a raw material for producing ACFs can be used as a raw material for producing the ACFs in the present invention, such as polyacrylonitrile (PAN)-based, phenolic, pitch, rayon, cellulose, aramid, polyimide, polyamide, polyamideimide, polyphenylenebenzobisoxazole, polyvinyl alcohol, polysulphoneether, polysulphone, polyphenylene oxide, and lignin.
  • PAN polyacrylonitrile
  • PAN polyacrylonitrile
  • phenolic, pitch-based, and rayon-based ACFs are more preferred due to their superior adsorption performance and/or productivity.
  • the ACFs in the present invention can be produced by the following methods, for example but not limited thereto. Commercially available ACFs may also be used.
  • the Polyacrylonitrile (PAN)-based ACFs can be obtained by oxidizing polyacrylonitrile-based fibers in the air, followed by activation.
  • the oxidation treatment is carried out at a temperature of 220 to 300°C over 0.1 to 10 hours.
  • the activation can include gas activation or chemical activation, and more preferred is gas activation.
  • As the activating gas steam and/or carbon dioxide, and even mixed gas composed of these gases and an inert gas such as nitrogen can be used.
  • the phenolic ACFs can be obtained by activating phenol novolak fibers. If curing (oxidation) is previously carried out in a liquid phase system or gas phase system, the production of the phenolic ACFs does not involve the oxidation treatment that is required for the polyacrylonitrile-based ACFs, and may involve only curing.
  • the pitch-based ACFs can be obtained by oxidizing fibers derived from petroleum- or coal-derived isotropic pitch material, followed by activation.
  • the rayon-based ACFs can obtained by oxidizing rayon in the air, followed by activation.
  • the ACFs in the present invention can be used in a mixture with one another, or in a mixture or combination with a conventional known spherical activated carbon (for example, Kremezin (registered trademark)) as a therapeutic or prophylactic drug for kidney diseases or dialysis complications.
  • a conventional known spherical activated carbon for example, Kremezin (registered trademark)
  • Kremezin registered trademark
  • the ACFs as the raw material may be activated again (reactivation).
  • Any type of ACFs as the raw material can be used, such as, for example, PAN-based, phenolic, pitch-based, and rayon-based ACFs.
  • the ACFs having a specific surface area of 300 m 2 /g or more and preferably 500 to 2500 m 2 /g can be used for reactivation.
  • the ACFs having a specific surface area of more than 2500 m 2 /g may increase the rate of reactivation so that it is difficult to control activation conditions. This may cause incineration, etc., and therefore a lower activation yield.
  • the activation conditions (type of the activating gas, temperature, duration, etc.) are similar to those used in the production of ACFs as the raw material.
  • the ACFs in the present invention may be subjected to surface desorption by a heat treatment in an inert gas at 400 to 1200°C at the late stage in the activation process of the ACFs or after the activation.
  • a temperature of more than 1200°C is not preferred since at the temperature, pores shrink to cause a decrease in the specific surface area, and therefore, preferred temperature is 1200°C or less.
  • the ACFs used in the heat treatment have any specific surface area, and preferred is 800 m 2 /g or more.
  • any inert gas can be used, such as nitrogen, argon, and helium gases.
  • the heat treatment may be carried out with a reducing gas such as hydrogen gas at an ambient temperature to 500°C.
  • the adsorbent for oral administration according to the present invention as a therapeutic or prophylactic drug for kidney diseases or dialysis complications comprises the above-mentioned ACFs as an active component.
  • the dosage form can be powder, granule, tablet, sugar-coated tablet, capsule, suspension, stick, individual packaging, jelly or emulsion.
  • an enteric-coated capsule can be also used as needed.
  • the adsorbent is used in the form of tablet, the tablet is required to be disintegrated into the original fibrous form.
  • the adsorbent may be used in the form of complex further compounded with other pharmaceutical agents such as lanthanum carbonate and sevelamer hydrochloride, or agents regulating electrolyte balance such as Kalimate and Kayexalate.
  • the adsorbent for oral administration according to the present invention can be used in any dosage form such as solid, semisolid, and liquid preparations.
  • a formulation according to the present invention is prepared using additives commonly used in pharmaceutical preparation.
  • additives include excipients such as lactose, white soft sugar, glucose, corn starch, potato starch, microcrystalline cellulose, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate, and calcium hydrogen phosphate; binders such as microcrystalline cellulose, carboxymethyl cellulose, hydroxypropylcellulose, sodiun carboxymethyl cellulose, and polyvinyl pyrrolidone; disintegrants such as starch, sodiun carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, and sodium carboxymethyl starch; lubricants such as talc and stearic acid; coating agents such as hydroxymethylpropylcellulose, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; and coloring agents for the solid preparation; bases such as white petrolatum for the semisolid preparation, and, solvents such as ethanol, solubil
  • the dose of an active component in the adsorbent for oral administration according to the present invention is usually about 1 to 3000 mg/day, more preferably about 1 to 1000 mg/day, and the dose frequency is usually once to 3 times/day.
  • the dose is usually about 6000 mg/day.
  • the adsorbent for oral administration according to the present invention can not only be used as a pharmaceutical uremic toxin adsorbent but also can be applied to use in the form where the adsorbent is contained in a beverage and food product or food additive, that is, as a uremic-toxin adsorbing beverage and food product or food additive.
  • the adsorbent may be compounded in an appropriate amount in the form of powder or liquid depending to the type or form of the base beverage and food product or food additive.
  • the beverage and food products into which the adsorbent is compounded include, for example, conventional solid food products (for example, biscuit, bread, and noodle), liquid food products (for example, soft drink, and health drink), and semi-liquid food products (for example, custard pudding, and jelly), and the food additives into which the adsorbent is compounded include, for example, conventional preservatives, antioxidants, sweeteners, colorants, emulsifying agents, seasonings, spices, and acidulants.
  • the kidney diseases can include, for example, chronic kidney disease, acute renal failure, chronic pyelonephritis, acute pyelonephritis, chronic glomerulonephritis, rapidly progressive nephritic syndrome, nephrotic syndrome, nephrosclerosis, interstitial nephritis, diabetic nephropathy, focal glomerulosclerosis, membranous nephropathy, polycystic kidney syndrome, renovascular hypertension, and hypertension syndrome, as well as secondary kidney diseases associated with the above-mentioned primary diseases (Non-patent Literature 10).
  • hyperphosphatemia, hyperkalemia, hyperuricemia, and hypernatremia accompanying chronic kidney disease can be included in kidney diseases in a broad sense.
  • the dialysis complications include, for example, pruritus, anemia, restless legs syndrome, cardiac failure, arteriosclerosis, dialysis amyloidosis, hyperphosphatemia, hyperkalemia, and pulmonary edema.
  • the activated carbon fibers according to the present invention are excellent in adsorptivity toward the uremic toxins in vivo such as indoxylsulfuric acid, indole, indoleacetic acid, guanidinoacetic acid, p-cresol, hippuric acid, furandicarboxylic acid, and homocysteine, as well as low-molecular-weight substances such as precursors thereof.
  • the activated carbon fibers have a beneficial selective adsorptivity, wherein the absorptivity toward substances beneficial for living organism, such as digestive enzymes (for example, amylase, trypsin, and lipase) is low.
  • uremic toxin refers to a harmful toxic substance that is responsible for uremia, including, in addition to uremic toxins themselves, precursors thereof.
  • the adsorbent for oral administration according to the present invention can hardly causes side effects such as constipation that would be caused by high doses, is excellent at adsorbing low-molecular-weight organic compounds that is a causative agent for uremia, shows sufficient adsorption performance even in low doses, and suppresses adsorption of high-molecular-weight compounds such as enzymes essential to living organism.
  • the adsorbent according to the present invention is effective as an adsorbent for oral administration, in particular, for patients presenting with pathological conditions such as chronic kidney disease in which toxins are accumulated in vivo.
  • the cross-sectional diameter of the fiber was calculated by the following method. Using an image analysis-based particle size/shape distribution measurement instrument PITA-II (from SEISHIN ENTERPRISE Co., LTD.) with a 4-times magnification lens, a total of 4000 to 8000 fiber shapes were measured by repeating multiple measurements.
  • PITA-II image analysis-based particle size/shape distribution measurement instrument
  • the numerical value obtained by dividing the "area" of the fiber imaged by the measurement instrument by "skeleton length" was defined as the fiber diameter of the fiber.
  • V represents the volume of the fiber
  • A represents the fiber diameter
  • B represents the fiber length.
  • the data for individual fibers are arranged in the order of increasing fiber diameter, the volume of each fiber is added in ascending order of the fiber diameter, and the fiber diameters when the sum reaches 10%, 50%, and 90% of the total volume were defined as cumulative 10%, 50%, and 90% of the fiber diameter (hereinafter, Dv10, Dv50, and Dv90), respectively.
  • the value Dv50 calculated was defined as the cross-sectional diameter of the fiber (average diameter).
  • the length of the fiber was calculated by the following method. Using an image analysis-based particle size/shape distribution measurement instrument PITA-II (from SEISHIN ENTERPRISE Co., LTD.) with a 4-times magnification lens, a total of 4000 to 8000 fiber shapes were measured by repeating multiple measurements.
  • PITA-II image analysis-based particle size/shape distribution measurement instrument
  • the “maximum length” of the fiber imaged by the measurement instrument was defined as the length of the fiber.
  • V represents the volume of the fiber
  • A represents the fiber diameter
  • B represents the fiber length.
  • the data for individual fibers are arranged in the order of increasing length of the fiber, the volume of each fiber is added in ascending order of the length of the fiber, and the lengths of the fiber when the sum reaches 10%, 50%, and 90% of the total volume were defined as cumulative 10%, 50%, and 90% of the length of the fiber (hereinafter, Dv10, Dv50, and Dv90) respectively.
  • Dv50 calculated was defined as the length of the fiber (average length).
  • the pore volume was determined from the adsorption isotherm of nitrogen by using density functional theory.
  • Total pore volume calculated from the total amount of the gas adsorbed at a relative pressure of near 1, assuming that pores are filled with liquid nitrogen.
  • Micropore volume Fiest, a pore having a pore size diameter of 20 ⁇ or less is defined as a micropore. Then, the pore volume of the pores having the diameter 20 ⁇ or less was calculated from the pore size obtained from the adsorption isotherm and the cumulative curve of pore volume.
  • Mesopore volume A pore having a pore size diameter of 20 to 100 ⁇ is defined as a mesopore. The pore volume was calculated from the pore size obtained from the adsorption isotherm and the cumulative curve of pore volume.
  • Macropore volume determined by subtracting the micropore volume and the mesopore volume from the total pore volume.
  • Polyacrylonitrile-based ACFs (fiber diameter 9 ⁇ m: trade name "FINEGARD : FW-510" from Toho Kako Kensetsu) were used. The properties of the ACFs are shown in Table 1.
  • Phenolic ACFs (fiber diameter 15 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO., LTD.) were used. The properties of the ACFs are shown in Table 1, the measured fiber lengths in Table 2, and the fiber length distribution in Fig. 3 .
  • Phenolnovolak fibers (fiber diameter 17 ⁇ m: trade name "KYNOL” from Gun Ei Chemical Industry Co., Ltd.) were activated with steam at 950°C for 120 minutes to obtain ACFs of the present invention.
  • the properties of the resulting ACFs are shown in Table 1.
  • Pitch-based ACFs fiber diameter 15 ⁇ m: trade name "A-15" from AD'ALL
  • the properties of the ACFs are shown in Table 1.
  • Oxidized polyacrylonitrile-based fibers (fiber diameter 14 ⁇ m: trade name "Pyromex" from TOHO TENAX Co., Ltd.) were activated with steam at 950°C for 60 minutes to obtain ACFs of the present invention.
  • the properties of the resulting ACFs are shown in Table 1.
  • Phenolic ACFs fiber diameter 15 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • KURACTIVE trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • Phenolic ACFs fiber diameter 15 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • KURACTIVE trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • Phenolic ACFs fiber diameter 15 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • KURACTIVE trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • Oxidized polyacrylonitrile-based fibers (fiber diameter 14 ⁇ m: trade name "Pyromex" from TOHO TENAX Co., Ltd.) were activated with steam at 950°C for 70 minutes to obtain ACFs of the present invention.
  • the properties of the resulting ACFs are shown in Table 1.
  • the ACFs prepared in Example 2 were subjected to classification using a circulating air flow sieving measurement instrument with a sieve having a mesh size of 10 ⁇ m after grinding. Materials that passed through the sieve were collected to obtain ACFs having a short fiber length.
  • the properties of the ACFs are shown in Table 1, the measured fiber lengths in Table 2, and the fiber length distribution in Fig. 4 .
  • Phenolic ACFs fiber diameter 16 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • the properties of the ACFs are shown in Table 1.
  • Phenolnovolak fibers (fiber diameter 12 ⁇ m: trade name "KYNOL” from Gun Ei Chemical Industry Co., Ltd.) were activated with steam at 900°C for 50 minutes to obtain ACFs of the present invention.
  • the properties of the ACFs are shown in Table 1, and the measured cross-sectional diameters of the fibers in Table 3.
  • Phenolnovolak fibers (fiber diameter 38 ⁇ m: trade name "KYNOL” from Gun Ei Chemical Industry Co., Ltd.) were activated with steam at 900°C for 50 minutes to obtain ACFs of the present invention.
  • the properties of the ACFs are shown in Table 1, and the measured cross-sectional diameters of the fibers in Table 3.
  • Phenolnovolak fibers (fiber diameter 17 ⁇ m: trade name "KYNOL” from Gun Ei Chemical Industry Co., Ltd.) were activated with steam at 500°C for 10 minutes to obtain ACFs of the present invention.
  • the specific surface area of the ACF was less than 600 m 2 /g.
  • Pitch-based ACFs fiber diameter 15 ⁇ m: trade name "A-20" from AD'ALL
  • the properties of the ACFs are shown in Table 1.
  • Rayon fibers (fiber diameter 31 ⁇ m) were treated with an aqueous ammonium phosphate solution, followed by oxidation treatment in air at 270°C for 2 hours, and then activation was carried out with steam at 900°C for 50 minutes to obtain ACFs of the present invention.
  • the properties of the ACFs are shown in Table 1.
  • Phenolic ACFs fiber diameter 15 ⁇ m: trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • KURACTIVE trade name "KURACTIVE” from KURARAY CHEMICAL CO.,LTD.
  • Phenolnovolak fibers (fiber diameter 17 ⁇ m: trade name "KYNOL” from Gun Ei Chemical Industry Co., Ltd.) were activated with steam at 900°C for 10 minutes to obtain ACFs of the present invention.
  • the properties of the ACFs are shown in Table 1.
  • KREMEZIN (registered trademark, KUREHA CORPORATION "KREMEZIN Fine Granule") was used.
  • Example 1 Specific surface area (m 2 /g) Total pore volume (mL/g) Micropore volume (mL/g) Mesopore volume (mL/g) Macropore volume (mL/g) Comparative Example 1 1400 0.83 0.51 0.25 0.07 Example 1 1440 1.08 0.43 0.60 0.05 Example 2 1420 0.81 0.66 0.05 0.10 Example 3 2190 1.45 0.79 0.45 0.21 Example 4 1240 0.70 0.48 0.20 0.05 Example 5 1300 0.81 0.44 0.30 0.10 Example 6 1935 1.30 0.76 0.39 0.14 Example 7 1467 1.01 0.62 0.24 0.15 Example 8 1520 1.00 0.64 0.24 0.11 Example 9 2098 1.38 0.63 0.66 0.10 Example 10 1132 0.81 0.48 0.19 0.14 Example 11 843 0.61 0.37 0.18 0.06 Example 12 1483 1.05 0.63 0.26 0.16 Example 13 1362 0.91 0.59 0.24 0.09 Example 15 1887 1.11 0.57 0.46 0.08 Example 16 1164 0.76 0.49 0.19 0.08 Example 17 2642 1.62 0.72 0.
  • the adsorption performance of the adsorbent for oral administration according to the present invention under conditions reflecting the state in which food is present in the digestive tract that is assumed to be a site at which an adsorbent exerts its activity, and to compare adsorption performance with the conventional adsorbent for oral administration, the adsorption performance in Ensure Liquid, an enteral nutrient (semidigest diet nutrient), was measured for the adsorbent for oral administration according to the present invention.
  • KREMEZIN registered trademark, KUREHA CORPORATION "KREMEZIN Fine Granule
  • the adsorption performance toward indoleacetic acid was measured by the following method over time.
  • Example 1 to 10 and the spherical activated carbon of Comparative Example 1 were dried at 115°C for 4 hours, and 25 mg of each of the samples was precisely weighed into separate polypropylene tubes.
  • a uremic toxin indoleacetic acid
  • Ensure Liquid from Abbott
  • the mixture was shaken at 37°C, and a part of the supernatant of the mixture was collected in 1, 3, 5, and 24 hours.
  • adsorption rate was expressed as the time period (h) required to adsorb 50%, assuming the amount of adsorption in 24 hours as 100%.
  • the ACFs of the present invention have much higher adsorption rates and higher adsorptivity for various ACFs from different raw materials, compared to the spherical activated carbon of Comparative Example 1. That is, the ACFs of the present invention can adsorb indoleacetic acid, a uremic toxin, rapidly, greatly, and persistently in an organic solution similar to the state in which food is present in the digestive tract.
  • the adsorbents for oral administration comprising ACFs of the present invention have a greatly superior uremic toxin adsorption performance compared to the adsorbent for oral administration comprising conventional spherical activated carbon.
  • the ACFs of Example 10 formed by collecting ones having a short fiber length out of the ACFs of Example 2 has a much lower uremic toxin adsorption performance than that of ACFs of Example 2. Based on these results, it is believed that the shape of a fiber in which the length is larger than the cross-sectional diameter, which is characteristic of fibers, is important for exhibiting a high adsorption performance.
  • the adsorbents for oral administration comprising fibrous activated carbon have a superior adsorption performance to the adsorbents for oral administration comprising conventional spherical activated carbon.
  • mice ICR, 8-9 weeks old, (CHARLES RIVER LABORATORIES JAPAN, INC., Japan SLC, Inc.) were divided into a vehicle treatment group, a Comparative Example treatment group and an Example treatment group (n 6 to 7) based on the body weight of mice so that there showed no bias in the body weight among groups.
  • the spherical activated carbon was administered at a dose of 5 mg, 15 mg, or 30 mg once daily to mice, while in the Example treatment group, the ACF was administered at a dose of 5 mg by gavage to mice.
  • blood was collected from abdominal aorta in the mice under anesthesia. After deproteinization of the collected serum with 85% acetonitrile, the serum levels of indoxylsulphuric acid were measured by LC-MS/MS (API4000 LC-MS/MS).
  • the ACFs of the present invention in a comparison between the ACFs of the present invention and the spherical activated carbon of Comparative Example 1, as shown in Table 5 and Fig. 2 , the ACFs of the present invention at a dose of 5 mg showed a high effect of reducing the serum levels of indoxylsulfuric acid for various ACFs from different raw materials while the spherical activated carbon of Comparative Example 1 hardly showed such an effect at the same dose.
  • the ACFs of the present invention at a dose of 5 mg showed a higher effect of reducing the serum levels of indoxylsulfuric acid for ACFs of Examples 11, 17 and 18 than that when the spherical activated carbon of Comparative Example 1 was administered at a dose of 15 mg, and the other ACFs showed a higher effect of reducing the serum levels of indoxylsulfuric acid than that when the spherical activated carbon of Comparative Example 1 was administered at a dose of 30 mg.
  • the adsorbents for oral administration comprising ACFs of the present invention are quite excellent in that the adsorbents have a greatly superior uremic toxin adsorptive activity compared to the adsorbents for oral administration comprising conventional spherical activated carbon, and can solve the problem of high doses associated with the adsorbents for oral administration comprising conventional spherical activated carbon.
  • the adsorbents for oral administration according to the present invention can be used for treating or preventing kidney diseases or dialysis complications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Carbon And Carbon Compounds (AREA)
  • External Artificial Organs (AREA)
EP12838141.5A 2011-10-07 2012-10-05 Orally administered adsorbent containing activated carbon fiber Active EP2772261B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SI201231142T SI2772261T1 (en) 2011-10-07 2012-10-05 An oral administration of an adsorbent containing activated carbon fibers
PL12838141T PL2772261T3 (pl) 2011-10-07 2012-10-05 Doustnie podawany adsorbent zawierający włókna węgla aktywowanego
RS20180154A RS56902B1 (sr) 2011-10-07 2012-10-05 Adsorbens koji sadrži aktivirana ugljenična vlakna za oralnu primenu
MEP-2018-38A ME02959B (me) 2011-10-07 2012-10-05 Adsorbens koji sadrži aktivirana ugljenična vlakna za oralnu primenu
HRP20171970TT HRP20171970T1 (hr) 2011-10-07 2017-12-19 Oralno primijenjeni adsorbent koji sadrži aktivno ugljično vlakno

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011222949 2011-10-07
JP2012181466 2012-08-20
PCT/JP2012/075897 WO2013051680A1 (ja) 2011-10-07 2012-10-05 経口投与用吸着剤

Publications (3)

Publication Number Publication Date
EP2772261A1 EP2772261A1 (en) 2014-09-03
EP2772261A4 EP2772261A4 (en) 2015-09-30
EP2772261B1 true EP2772261B1 (en) 2017-11-22

Family

ID=48043833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12838141.5A Active EP2772261B1 (en) 2011-10-07 2012-10-05 Orally administered adsorbent containing activated carbon fiber

Country Status (29)

Country Link
US (1) US9682046B2 (pt)
EP (1) EP2772261B1 (pt)
JP (1) JP5781164B2 (pt)
KR (1) KR101890458B1 (pt)
CN (1) CN103841981B (pt)
AR (1) AR088255A1 (pt)
AU (1) AU2012319495B2 (pt)
BR (1) BR112014008230A2 (pt)
CA (1) CA2851215C (pt)
CY (1) CY1119877T1 (pt)
DK (1) DK2772261T3 (pt)
ES (1) ES2655176T3 (pt)
HR (1) HRP20171970T1 (pt)
HU (1) HUE036432T2 (pt)
IL (1) IL231680B (pt)
LT (1) LT2772261T (pt)
ME (1) ME02959B (pt)
MX (1) MX362027B (pt)
MY (1) MY167387A (pt)
NO (1) NO2772261T3 (pt)
PL (1) PL2772261T3 (pt)
PT (1) PT2772261T (pt)
RS (1) RS56902B1 (pt)
RU (1) RU2583934C2 (pt)
SG (1) SG11201401320QA (pt)
SI (1) SI2772261T1 (pt)
TW (1) TWI625122B (pt)
WO (1) WO2013051680A1 (pt)
ZA (1) ZA201402500B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
US20170290856A1 (en) * 2014-09-24 2017-10-12 Power Japan Plus Inc. Oral adsorbent and method for producing oral adsorbent
CN104666342A (zh) * 2015-01-12 2015-06-03 精秐生物科技（上海）有限公司 可降低体内尿毒素的吸附剂
GB2537168A (en) * 2015-04-10 2016-10-12 Bio-Medical Carbon Tech Co Ltd Adsorbent for reducing uremic toxins in vivo
US20160296558A1 (en) * 2015-04-10 2016-10-13 Bio-Medical Carbon Technology Co., Ltd. Adsorbent for reducing uremic toxins in vivo
WO2017205806A1 (en) * 2016-05-27 2017-11-30 Gastroklenz Inc. Systems and methods for gastric dialysis
JP7202285B2 (ja) 2017-03-31 2023-01-11 株式会社アドール 活性炭の製造方法
RU2690951C1 (ru) * 2018-08-02 2019-06-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ профилактики инфекционных осложнений, связанных с установкой перитонеального катетера, у больных хронической болезнью почек с5 на перитонеальном диализе
JP7309436B2 (ja) * 2019-04-26 2023-07-18 森永乳業株式会社 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
JP7478163B2 (ja) * 2019-11-01 2024-05-02 株式会社クラレ めっき液精製用吸着フィルター、並びに、それを用いためっき液精製装置及びめっき液精製方法
CN116036034B (zh) * 2023-03-31 2023-06-02 北京佳福瑞生物科技有限公司 一种用于神经精神类疾病治疗的复合药剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008602A (ja) * 2004-06-25 2006-01-12 Ajinomoto Co Inc 経口尿毒症毒素吸着剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565313A (en) 1979-06-26 1981-01-20 Kureha Chem Ind Co Ltd Detoxificating spherical active carbon and preparing the same
JPS62223125A (ja) 1979-06-26 1987-10-01 Kureha Chem Ind Co Ltd 経口解毒剤
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
RU2069560C1 (ru) 1992-02-27 1996-11-27 Ленинградское хозрасчетное научно-производственное предприятие "Медход" Вещество для адсорбции ядов
RU2057533C1 (ru) 1992-07-26 1996-04-10 Владимир Григорьевич Николаев Активированный углеволокнистый энтеросорбент
AU6471696A (en) 1996-07-22 1998-02-10 Kouki Bussan Yugenkaisha Novel adsorbent
JP2001164430A (ja) 2000-10-11 2001-06-19 Osaka Gas Co Ltd 活性炭繊維
AU2003242363A1 (en) 2002-05-22 2003-12-02 Japan Energy Corporation Adsorption desulfurization agent for desulfurizing petroleum fraction and desulfurization method using the same
TWI341732B (en) 2002-11-01 2011-05-11 Kureha Corp Adsorbent for oral administration,agent for treating or preventing renal disease, and
US7651974B2 (en) * 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
AU2003280690A1 (en) 2002-11-01 2004-05-25 Kureha Chemical Industry Co., Ltd. Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases
CN1263466C (zh) * 2003-05-06 2006-07-12 陈小川 活性炭输液剂、其制备方法及其在制备治疗癌症药中的应用
JP4378612B2 (ja) 2003-11-07 2009-12-09 東洋紡績株式会社 有機化合物吸着用繊維状活性炭およびそれを用いた排ガス処理装置
WO2005060980A1 (ja) 2003-12-24 2005-07-07 Masaakira Shonago 疾患治療用医薬及び糖尿病治療用医薬
EP1701752B1 (en) 2003-12-24 2016-05-18 Chemica Technologies, Inc. Dialysate regeneration system for portable human dialysis
JP2005232138A (ja) 2004-02-23 2005-09-02 Hokkaido Soda Kk 生体内有害物質用吸着剤
JP4875840B2 (ja) 2004-07-30 2012-02-15 トーアエイヨー株式会社 経口投与用活性炭製剤
CN100441166C (zh) 2005-01-17 2008-12-10 闫彬 一种包含大黄和活性碳或药用碳的药物组合物
JP5080042B2 (ja) 2006-08-31 2012-11-21 大阪ガスケミカル株式会社 シロキサンガス除去用吸着剤及びシロキサンガス除去用フィルタ
JP5376592B2 (ja) 2009-10-15 2013-12-25 産協企業有限股▲ふん▼公司 球形活性炭及びその製造方法
JP5482133B2 (ja) * 2009-11-17 2014-04-23 東洋紡株式会社 活性炭素繊維
JP5327009B2 (ja) 2009-11-17 2013-10-30 東洋紡株式会社 活性炭素繊維
CN102140708B (zh) 2011-01-27 2012-09-12 济南大学 一种活性炭纤维及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008602A (ja) * 2004-06-25 2006-01-12 Ajinomoto Co Inc 経口尿毒症毒素吸着剤

Also Published As

Publication number Publication date
KR101890458B1 (ko) 2018-08-21
HRP20171970T1 (hr) 2018-02-09
MX362027B (es) 2019-01-04
ES2655176T3 (es) 2018-02-19
US20140242147A1 (en) 2014-08-28
US9682046B2 (en) 2017-06-20
TWI625122B (zh) 2018-06-01
SG11201401320QA (en) 2014-07-30
AU2012319495B2 (en) 2017-07-20
CN103841981B (zh) 2016-11-16
TW201328700A (zh) 2013-07-16
CA2851215C (en) 2021-01-19
JP5781164B2 (ja) 2015-09-16
LT2772261T (lt) 2018-02-12
ME02959B (me) 2018-07-20
EP2772261A4 (en) 2015-09-30
PL2772261T3 (pl) 2018-06-29
JPWO2013051680A1 (ja) 2015-03-30
CY1119877T1 (el) 2018-06-27
DK2772261T3 (en) 2018-01-08
AR088255A1 (es) 2014-05-21
NO2772261T3 (pt) 2018-04-21
MY167387A (en) 2018-08-16
AU2012319495A1 (en) 2014-04-24
CA2851215A1 (en) 2013-04-11
WO2013051680A1 (ja) 2013-04-11
PT2772261T (pt) 2018-01-08
RU2014118448A (ru) 2015-11-20
EP2772261A1 (en) 2014-09-03
IL231680A0 (en) 2014-05-28
MX2014003791A (es) 2014-07-09
RS56902B1 (sr) 2018-05-31
RU2583934C2 (ru) 2016-05-10
CN103841981A (zh) 2014-06-04
SI2772261T1 (en) 2018-02-28
IL231680B (en) 2018-08-30
KR20140072077A (ko) 2014-06-12
HUE036432T2 (hu) 2018-07-30
BR112014008230A2 (pt) 2017-04-11
NZ623528A (en) 2016-04-29
ZA201402500B (en) 2015-03-25

Similar Documents

Publication Publication Date Title
EP2772261B1 (en) Orally administered adsorbent containing activated carbon fiber
TWI319985B (en) Adsorbent for oral administration, agent for treating or preventing renal disease, and agent for treating or preventing liver disease
EP2628483B1 (en) Medical adsorbent and method for producing same
JP2006256882A (ja) 活性炭及びその製造方法並びに腎肝疾患治療薬
JP4693030B2 (ja) 活性炭の製造方法
KR20050042263A (ko) 경구투여용 흡착제
KR101748413B1 (ko) 흡착탄 및 흡착제
JP5985027B2 (ja) 経口投与用医薬用吸着剤の製造方法
NZ623528B2 (en) Orally administered adsorbent
EP1407772B9 (en) Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
TWI314863B (en) Adsorbent for oral administration and pharmaceutical composition, and method of manufacturing absorbent for oral administration
JP2021161100A (ja) 経口投与用錠剤型吸着剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 13/02 20060101ALI20150430BHEP

Ipc: C01B 31/10 20060101ALI20150430BHEP

Ipc: D01F 9/22 20060101ALI20150430BHEP

Ipc: D01F 9/14 20060101ALI20150430BHEP

Ipc: A61P 7/08 20060101ALI20150430BHEP

Ipc: A61P 39/02 20060101ALI20150430BHEP

Ipc: A61K 33/44 20060101AFI20150430BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150902

RIC1 Information provided on ipc code assigned before grant

Ipc: D01F 9/14 20060101ALI20150827BHEP

Ipc: A61P 39/02 20060101ALI20150827BHEP

Ipc: A61P 7/08 20060101ALI20150827BHEP

Ipc: D01F 9/22 20060101ALI20150827BHEP

Ipc: A61K 33/44 20060101AFI20150827BHEP

Ipc: C01B 31/10 20060101ALI20150827BHEP

Ipc: A61P 13/02 20060101ALI20150827BHEP

17Q First examination report despatched

Effective date: 20160722

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: D01F 9/14 20060101ALI20170413BHEP

Ipc: B01J 20/28 20060101ALI20170413BHEP

Ipc: D01F 9/22 20060101ALI20170413BHEP

Ipc: A61K 33/44 20060101AFI20170413BHEP

Ipc: B01J 20/20 20060101ALI20170413BHEP

Ipc: A61K 9/70 20060101ALI20170413BHEP

Ipc: A61P 39/02 20060101ALI20170413BHEP

Ipc: A61P 7/08 20060101ALI20170413BHEP

Ipc: A61P 13/02 20060101ALI20170413BHEP

INTG Intention to grant announced

Effective date: 20170518

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 947777

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A., CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20171970

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012040179

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180104

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2772261

Country of ref document: PT

Date of ref document: 20180108

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171229

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20171970

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E014706

Country of ref document: EE

Effective date: 20171205

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2655176

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180219

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20171122

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 26258

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400396

Country of ref document: GR

Effective date: 20180627

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E036432

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012040179

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

26N No opposition filed

Effective date: 20180823

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: TEIJIN LIMITED

Effective date: 20190131

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20190124 AND 20190130

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 947777

Country of ref document: AT

Kind code of ref document: T

Owner name: TEIJIN LIMITED, JP

Effective date: 20190206

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED

Effective date: 20190206

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20190206

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 947777

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171122

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: TEIJIN LIMITED, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, JP

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20190506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012040179

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012040179

Country of ref document: DE

Owner name: TEIJIN LIMITED, OSAKA-SHI, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012040179

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012040179

Country of ref document: DE

Owner name: TEIJIN LIMITED, OSAKA-SHI, JP

Free format text: FORMER OWNER: TEIJIN LIMITED, OSAKASHI-SHI, OSAKA, JP

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E014706

Country of ref document: EE

REG Reference to a national code

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Ref country code: HU

Ref legal event code: GB9C

Owner name: TEIJIN LIMITED, JP

Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED, JP

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: TEIJIN LIMITED; JP

Effective date: 20190624

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 26258

Country of ref document: SK

Owner name: TEIJIN LIMITED, OSAKA-SHI, OSAKA, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, CHIYODA-KU, TOKYO, JP

Effective date: 20190722

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20171970

Country of ref document: HR

Owner name: TEIJIN LIMITED, JP

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: TEIJIN LIMITED, JP

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171970

Country of ref document: HR

Payment date: 20190923

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171970

Country of ref document: HR

Payment date: 20200929

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171970

Country of ref document: HR

Payment date: 20210923

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20210924

Year of fee payment: 10

Ref country code: SM

Payment date: 20210927

Year of fee payment: 10

Ref country code: HR

Payment date: 20210923

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20210924

Year of fee payment: 10

Ref country code: PL

Payment date: 20210928

Year of fee payment: 10

Ref country code: RO

Payment date: 20210923

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20210922

Year of fee payment: 10

Ref country code: PT

Payment date: 20210923

Year of fee payment: 10

Ref country code: NL

Payment date: 20211020

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20211005

Year of fee payment: 10

Ref country code: SE

Payment date: 20211020

Year of fee payment: 10

Ref country code: TR

Payment date: 20211001

Year of fee payment: 10

Ref country code: AT

Payment date: 20211021

Year of fee payment: 10

Ref country code: CZ

Payment date: 20211005

Year of fee payment: 10

Ref country code: BG

Payment date: 20211021

Year of fee payment: 10

Ref country code: GB

Payment date: 20211022

Year of fee payment: 10

Ref country code: FI

Payment date: 20211021

Year of fee payment: 10

Ref country code: DK

Payment date: 20211022

Year of fee payment: 10

Ref country code: ES

Payment date: 20211224

Year of fee payment: 10

Ref country code: EE

Payment date: 20211019

Year of fee payment: 10

Ref country code: MC

Payment date: 20211025

Year of fee payment: 10

Ref country code: LU

Payment date: 20211020

Year of fee payment: 10

Ref country code: IE

Payment date: 20211020

Year of fee payment: 10

Ref country code: NO

Payment date: 20211022

Year of fee payment: 10

Ref country code: DE

Payment date: 20211020

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20210923

Year of fee payment: 10

Ref country code: LV

Payment date: 20211020

Year of fee payment: 10

Ref country code: IT

Payment date: 20211028

Year of fee payment: 10

Ref country code: IS

Payment date: 20211012

Year of fee payment: 10

Ref country code: HU

Payment date: 20211020

Year of fee payment: 10

Ref country code: GR

Payment date: 20211025

Year of fee payment: 10

Ref country code: FR

Payment date: 20211022

Year of fee payment: 10

Ref country code: CH

Payment date: 20211020

Year of fee payment: 10

Ref country code: BE

Payment date: 20211020

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20210927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20211004

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20211021

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20171970

Country of ref document: HR

Effective date: 20221005

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012040179

Country of ref document: DE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E014706

Country of ref document: EE

Effective date: 20221031

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 26258

Country of ref document: SK

Effective date: 20221005

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20221031

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 947777

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221005

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230522

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230405

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221101

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230503

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005